Press Releases

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has developed a new reagent, Optimer®-Fc, for use in automated immunohistochemistry (IHC) workflows. Optimer-Fc tools consist of an Optimer binder conjugated to the Fc domain of an antibody. The Company has successfully demonstrated the functional integration of different Optimer binders into this conjugate format. This allows the broad target rang

Elegen, a leader in DNA innovation, today announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution. Elegen’s ENFINIA™ DNA represents a major advance in the field, offering an unprecedented combination of length, speed, and accuracy to streamline synthetic biology workflows and scale to meet the demands of the growing bioeconomy.

InvoX Pharma Limited a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody. Under the terms of the licence agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody

Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases. The data was presented during the 2023 American Academy of Dermatology (AAD) conference week, a gathering of the largest, most influential, and representative dermatology gro

With its uniqueness and creativity to deliver the best learning experience for its attendees, Eminence Business Media has yet again delivered one-of-a-kind programs to cater to the needs of the industry in the best possible way. The 3rd Annual GMP & Quality Management 2023 was designed with a unique approach of an amalgamating format of virtual and in-person conference for

Pharmanovia, a global pharmaceutical company that commercializes new medicines and revitalizes, extends and extends the cycle of established medicines, today announced the expansion of its endocrinology portfolio with a new licensing agreement for GHRYVELIN™ (macimorelin), a new medication applied to diagnose Growth Hormone Deficiency (GHD) in adults from Aeterna Zentaris. The release in the original language is the official and authorized version thereof. This translation is

Avantor, a leading global provider of mission-critical products and services to customers in the life sciences, education, government and advanced technologies & applied materials industries, has been accorded the Best Bioprocessing Company for Chromatography at the Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA). The award recognizes Avantor's ongoing efforts to provide innovative chromatography solutions that enable biopharmaceutical manufacturers to optimize proc

HanAll Biopharma Co., Ltd. a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, is now accepting applications for the 2023 pharmaceutical industry fellowship program through April 15, 2023. The program is open to physicians trained in Indonesia, who have a strong interest in working for a global biopharma company. The Pharmaceutical Industry Fellowship Program, which runs from September 2023 to September 2025, offers intensive

lino Biotech, a leading biosensor company and the world's only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to s

Ellipses Pharma  a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML). The FDA grants ODD based on review of promising early clinical data from investigational treatment